P. Sharma, S. Hu-Lieskovan, J.A. Wargo, A. Ribas, Primary, adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 168(4), 707–723 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Terme, S. Pernot, E. Marcheteau, F. Sandoval, N. Benhamouda, O. Colussi, O. Dubreuil, A.F. Carpentier, E. Tartour, J. Taieb, VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73(2), 539–549 (2013)

Article  CAS  PubMed  Google Scholar 

C.L. Roland, S.P. Dineen, K.D. Lynn, L.A. Sullivan, M.T. Dellinger, L. Sadegh, J.P. Sullivan, D.S. Shames, R.A. Brekken, Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 8(7), 1761–1771 (2009)

Article  CAS  PubMed  Google Scholar 

B. Ljungberg, L. Albiges, Y. Abu-Ghanem, J. Bedke, U. Capitanio, S. Dabestani, S. Fernandez-Pello, R.H. Giles, F. Hofmann, M. Hora, T. Klatte, T. Kuusk, T.B. Lam, L. Marconi, T. Powles, R. Tahbaz, A. Volpe, A. Bex, European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 Update. Eur. Urol. 82(4), 399–410 (2022)

Article  PubMed  Google Scholar 

B.I. Rini, E.R. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulieres, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S.J. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R.S. McDermott, J. Bedke, S. Tartas, Y.H. Chang, S. Tamada, Q. Shou, R.F. Perini, M. Chen, M.B. Atkins, T. Powles, Investigators Keynote-. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 380(12), 1116–1127 (2019)

Article  CAS  PubMed  Google Scholar 

R.J. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges, M.T. Campbell, B. Venugopal, C. Kollmannsberger, S. Negrier, M. Uemura, J.L. Lee, A. Vasiliev, W.H. Jr. Miller, H. Gurney, M. Schmidinger, J. Larkin, M.B. Atkins, J. Bedke, B. Alekseev, J. Wang, M. Mariani, P.B. Robbins, A. Chudnovsky, C. Fowst, S. Hariharan, B. Huang, di A. Pietro, T.K. Choueiri, Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 380(12), 1103–1115 (2019)

Article  CAS  PubMed  Google Scholar 

T.K. Choueiri, T. Powles, M. Burotto, B. Escudier, M.T. Bourlon, B. Zurawski, V.M. Oyervides Juarez, J.J. Hsieh, U. Basso, A.Y. Shah, C. Suarez, A. Hamzaj, J.C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J.P. Feregrino, J. Zolnierek, D. Pook, E.R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M.A. Maurer, B. Simsek, F. Ejzykowicz, G.M. Schwab, A.B. Apolo, R.J. Motzer, CheckMate E. R. investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl. J. Med. 384(9), 829–841 (2021)

Article  CAS  PubMed  Google Scholar 

R. Motzer, B. Alekseev, S.Y. Rha, C. Porta, M. Eto, T. Powles, V. Grunwald, T.E. Hutson, E. Kopyltsov, M.J. Mendez-Vidal, V. Kozlov, A. Alyasova, S.H. Hong, A. Kapoor, T. Alonso Gordoa, J.R. Merchan, E. Winquist, P. Maroto, J.C. Goh, M. Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, De U. Giorgi, S. Wong, J. Bedke, M. Schmidinger, C.E. Dutcus, A.D. Smith, L. Dutta, K. Mody, R.F. Perini, D. Xing, Choueiri T. K., investigators clear Trial. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl. J. Med. 384(14), 1289–1300 (2021)

Article  CAS  PubMed  Google Scholar 

Y. Matsuyama, M. Suzuki, C. Arima, Q.M. Huang, S. Tomida, T. Takeuchi, R. Sugiyama, Y. Itoh, Y. Yatabe, H. Goto, T. Takahashi, Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Mol. Carcinog. 50(4), 301–309 (2011)

Article  CAS  PubMed  Google Scholar 

W.H. Wang, S.K. Chen, H.C. Huang, H.F. Juan, Proteomic analysis reveals that metformin suppresses PSMD2, STIP1, and CAP1 for preventing gastric Cancer AGS Cell Proliferation and Migration. ACS Omega. 6(22), 14208–14219 (2021)

Article  CAS  PubMed  Google Scholar 

A. Naderi, A.E. Teschendorff, N.L. Barbosa-Morais, S.E. Pinder, A.R. Green, D.G. Powe, J.F. Robertson, S. Aparicio, I.O. Ellis, J.D. Brenton, C. Caldas, A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 26(10), 1507–1516 (2007)

Article  CAS  PubMed  Google Scholar 

R. Tian, J. Tian, X. Zuo, S. Ren, H. Zhang, H. Liu, Z. Wang, Y. Cui, R. Niu, F. Zhang, RACK1 facilitates breast cancer progression by competitively inhibiting the binding of beta-catenin to PSMD2 and enhancing the stability of beta-catenin. Cell. Death Dis. 14(10), 685 (2023)

Article  CAS  PubMed  Google Scholar 

K. Ying, C. Wang, S. Liu, Y. Kuang, Q. Tao, X. Hu, Diverse ras-related GTPase DIRAS2, downregulated by PSMD2 in a proteasome-mediated way, inhibits colorectal cancer proliferation by blocking NF-kappaB signaling. Int. J. Biol. Sci. 18(3), 1039–1050 (2022)

Article  CAS  PubMed  Google Scholar 

Y. Liu, M. Wu, S. Xu, X. Niu, W. Liu, C. Miao, A. Lin, Y. Xu, L. Yu, PSMD2 contributes to the progression of esophageal squamous cell carcinoma by repressing autophagy. Cell. Biosci. 13(1), 67 (2023)

Article  CAS  PubMed  Google Scholar 

Q. Xiong, S. Fischer, M. Karow, R. Muller, S. Messling, L. Eichinger, ATG16 mediates the autophagic degradation of the 19S proteasomal subunits PSMD1 and PSMD2. Eur. J. Cell. Biol. 97(8), 523–532 (2018)

Article  CAS  PubMed  Google Scholar 

Z. Wang Jiajun, W. Sihong, Z. Ying, X. Yanjun, G.J. Xianglai, Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. Urol Oncol. 41(1), 51.e13–51.e23 (2023)

E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228–247 (2009)

Article  CAS  PubMed  Google Scholar 

R.J. Motzer, P.B. Robbins, T. Powles, L. Albiges, J.B. Haanen, J. Larkin, X.J. Mu, K.A. Ching, M. Uemura, S.K. Pal, B. Alekseev, G. Gravis, M.T. Campbell, K. Penkov, J.L. Lee, S. Hariharan, X. Wang, W. Zhang, J. Wang, A. Chudnovsky, di A. Pietro, A.C. Donahue, T.K. Choueiri, Avelumab plus Axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat. Med. 26(11), 1733–1741 (2020)

Article  CAS  PubMed  Google Scholar 

J. Wang, S. Zhang, Y. Wang, Y. Zhu, X. Xu, J. Guo, Alternative complement pathway signature determines immunosuppression and resistance to immunotherapy plus tyrosine kinase inhibitor combinations in renal cell carcinoma. Urol. Oncol. (2022)

M.J. Goldman, B. Craft, M. Hastie, K. Repecka, F. McDade, A. Kamath, A. Banerjee, Y. Luo, D. Rogers, A.N. Brooks, J. Zhu, D. Haussler, Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38(6), 675–678 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.K. Swisher, Y. Wu, C.A. Castaneda, G.R. Lyons, F. Yang, C. Tapia, X. Wang, S.A. Casavilca, R. Bassett, M. Castillo, A. Sahin, E.A. Mittendorf, Interobserver Agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast Cancer using methodology proposed by the International TILs Working Group. Ann. Surg. Oncol. 23(7), 2242–2248 (2016)

Article  PubMed  Google Scholar 

J. Wang, L. Liu, Q. Bai, C. Ou, Y. Xiong, Y. Qu, Z. Wang, Y. Xia, J. Guo, J. Xu, Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 8(1), e1515611 (2019)

Article  PubMed  Google Scholar 

W. Xu Xianglai, C. Ying, Z. Zhaoyi, W. Yanjun, G. Jiajun, Jianming. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Immunogenetics (2022)

T. Wu, E. Hu, S. Xu, M. Chen, P. Guo, Z. Dai, T. Feng, L. Zhou, W. Tang, L. Zhan, X. Fu, S. Liu, X. Bo, G. Yu, clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innov. (Camb). 2(3), 100141 (2021)

CAS  Google Scholar 

M.S. Ernst, N.V. Wells, J.C. Donskov, F. Basappa, N. Labaki, C. Pal, S.K. Meza, L. Wood, L.A. Ernst, D.S. Szabados, B. McKay, R.R. Parnis, F. Suarez, C. Yuasa, T. Lalani, A.K. Alva, A. Bjarnason, G.A. Choueiri, T.K. Heng, Y. C. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic groups in Contemporary First-line combination therapies for metastatic renal cell carcinoma. Eur. Urol. 84(1), 109–116 (2023)

Article  CAS  PubMed  Google Scholar 

J.J. Ko, W. Xie, N. Kroeger, J.L. Lee, B.I. Rini, J.J. Knox, G.A. Bjarnason, S. Srinivas, S.K. Pal, T. Yuasa, M. Smoragiewicz, F. Donskov, R. Kanesvaran, L. Wood, D.S. Ernst, N. Agarwal, U.N. Vaishampayan, S.Y. Rha, T.K. Choueiri, D.Y. Heng, The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 16(3), 293–300 (2015)

Article  PubMed  Google Scholar 

D.A. Braun, Y. Hou, Z. Bakouny, M. Ficial, M. Sant’ Angelo, J. Forman, P. Ross-Macdonald, A.C. Berger, O.A. Jegede, L. Elagina, J. Steinharter, M. Sun, M. Wind-Rotolo, J.C. Pignon, A.D. Cherniack, L. Lichtenstein, D. Neuberg, P. Catalano, G.J. Freeman, A.H. Sharpe, D.F. McDermott, Van E.M. Allen, S. Signoretti, C.J. Wu, S.A. Shukla, Choueiri T. K. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26(6), 909–918 (2020)

Article  CAS  PubMed  Google Scholar 

D.F. McDermott, M.A. Huseni, M.B. Atkins, R.J. Motzer, B.I. Rini, B. Escudier, L. Fong, R.W. Joseph, S.K. Pal, J.A. Reeves, M. Sznol, J. Hainsworth, W.K. Rathmell, W.M. Stadler, T. Hutson, M.E. Gore, A. Ravaud, S. Bracarda, C. Suarez, R. Danielli, V. Gruenwald, T.K. Choueiri, D. Nickles, J.S. Piault-Louis, E. Thobhani, A. Qiu, J. Chen, D.S. Hegde, P.S. Schiff, C. Fine, G.D. Powles, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24(6), 749–757 (2018)

Article  CAS  PubMed